GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal

City AM — Jun 09, 06:28 AM

GSK will acquire Nuvalent for $10.6bn. https://www.cityam.com/wp-content/uploads/2026/01/gsk-logo-e1768906854508.jpg?w=1107" />

Pharma giant GSK has sealed a $10bn deal to snap up Boston-based biopharmaceutical company Nuvalent.

The FTSE 100 titan said it will pay $124 per share in cash in the agreement, marking a 40 per cent premium over what Nuvalent’s stock was trading at just before this announcement.

The deal is expected to officially close https://www.cityam.com/gsk-snaps-up-us-cancer-treatment-firm-nuvalent-in-10-6bn-deal/">[...]

Read full article at City AM →

GSK Acquires Nuvalent for $10.6 Billion

GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down MarketWatch — Jun 09, 07:37 AM
GSK to buy US cancer treatment firm Nuvalent for $10.6bn The Guardian — Jun 09, 07:28 AM
GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Argus — Jun 09, 07:08 AM
GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Standard — Jun 09, 07:08 AM
GSK agrees to buy US cancer drug firm Nuvalent in £8bn deal Yorkshire Post — Jun 09, 08:21 AM